McKinney, August 21, 2025
News Summary
OSPRI, a new biotechnology company, has formed through a $30 million merger of Community Direct DX, Scienetix, and the R&D division of Advanta Genetics. The company aims to lead in PCR-based infectious disease detection, improving testing efficiency and accessibility across healthcare settings. With significant funding from Catalio Capital Management, OSPRI plans to increase its operational capacity, expand its workforce, and optimize resources for high-complexity testing, ultimately enhancing service deliverability in 20 states.
McKinney — A new biotechnology company, OSPRI, has been formed through a $30 million merger that combines Community Direct DX (CDx), Scienetix, and the research and development division of Advanta Genetics. The company positions itself as a leader in polymerase chain reaction (PCR)-based infectious disease detection and has secured strategic funding of up to $30 million from Catalio Capital Management to support platform development and growth.
Top-line overview
OSPRI is structured to offer an end-to-end solution for infectious disease testing that spans manufacturing, laboratory buildout, revenue cycle management, and regulatory support. The company’s stated objective is to reduce cost and complexity in PCR testing to expand adoption across multiple healthcare settings, including women’s health, primary care, urgent care, urology, hospitals, and clinical reference laboratories.
Operational capacity and reach
OSPRI reports a significant increase in production capacity following the merger, now delivering more than 40,000 tests per day while maintaining multilayered quality control processes. The company currently serves clients across 20 states and across a range of clinical specialties. One of the predecessor organizations, Community Direct DX, has a track record of launching over 60 labs nationwide, providing a foundation for OSPRI’s rapid expansion plans.
Services and technical focus
The company’s offerings target the practical needs of healthcare providers that seek to operate high-complexity laboratories in-house. OSPRI’s integrated services include lab design and buildout, equipment manufacturing where applicable, clinical regulatory support, and revenue cycle management to help providers manage financial performance. The combined capabilities of the merged entities are intended to deliver faster turnaround times, cost savings, and operational efficiencies for PCR-based infectious disease testing.
Funding and strategic backing
OSPRI has received strategic funding of up to $30 million from Catalio Capital Management to underwrite growth, technology development, and commercialization of its testing platform. The funding is intended to accelerate R&D efforts, expand commercial operations, and broaden service reach. Catalio’s support is framed as enabling simplification of infectious disease testing while creating both clinical and commercial value through the platform.
Leadership and expertise
OSPRI’s leadership team brings combined expertise from the merged companies. Key leadership roles include a Chief Science Officer, a Chief Innovation Officer, and a Chief Clinical Officer, reflecting the company’s emphasis on scientific rigor, product innovation, and clinical integration. The merged entities contribute distinct areas of expertise: Community Direct DX with lab operations and market rollout experience, Scienetix with molecular bioengineering capabilities, and Advanta R&D with advanced work in high-resolution genomics.
Workforce and growth targets
The company plans workforce expansion in both research and commercial areas, with a target to increase the R&D team by 40% and grow commercial operations by 25% within the next 12 to 24 months. Those targets are intended to support ramped-up production, broadened service offerings, and deeper market penetration across clinical segments and geographies.
Clinical and market context
PCR testing has historically been limited in wider use by high costs and operational complexity. OSPRI’s stated aim is to make PCR testing faster, less expensive, and more efficient, enabling a broader set of providers to deliver high-quality infectious disease testing on-site. The company’s model focuses on enabling providers to retain clinical control and manage financial returns by bringing high-complexity testing capabilities in-house rather than relying exclusively on external reference laboratories.
Quality control and regulatory approach
OSPRI emphasizes multilayered quality control systems and regulatory support as core components of its service model. The integrated approach is designed to align laboratory buildout, test validation, and ongoing quality assurance with applicable clinical laboratory standards and regulatory requirements, supporting providers that will operate CLIA high-complexity labs.
Outlook and next steps
Following the merger and investment, OSPRI plans to continue expanding its platform, scale laboratory operations, and invest in R&D to improve throughput and cost-efficiency for PCR-based infectious disease testing. The company’s near-term priorities include staffing growth, commercial expansion into additional states and clinical specialties, and further development of product and operational capabilities to support provider-led laboratory services.
FAQ
What is OSPRI?
OSPRI is a McKinney-based biotechnology company created by a $30 million merger of Community Direct DX, Scienetix, and the R&D division of Advanta Genetics. It focuses on PCR-based infectious disease testing and offers integrated laboratory and commercialization services.
What services does OSPRI provide?
OSPRI provides an end-to-end offering including manufacturing, lab buildout, revenue cycle management, regulatory support, and operational systems to help healthcare providers run high-complexity PCR testing in-house.
How is OSPRI funded?
The company secured strategic funding of up to $30 million from Catalio Capital Management to support growth, platform development, and commercialization.
What is OSPRI’s current capacity and reach?
OSPRI reports the ability to deliver over 40,000 tests per day and serves clients across 20 states and multiple clinical specialties.
What are OSPRI’s growth plans?
OSPRI plans to grow its R&D team by around 40% and expand commercial operations by approximately 25% within the next 12 to 24 months.
Key features
| Feature | Value | Visual |
|---|---|---|
| Merger value | $30 million |
|
| Daily testing capacity | 40,000+ tests/day |
|
| States served | 20 states |
|
| R&D growth target | +40% |
|
| Commercial growth target | +25% |
|
Deeper Dive: News & Info About This Topic
HERE Resources
Texas Enhances Business Dispute Resolution Framework
Startup Texas Accelerator Applications Open for Brownsville Entrepreneurs
Dallas-Fort Worth Emerges as a Leading Hub for Life Sciences Growth
Regeneron Acquires 23andMe for $256 Million
Additional Resources
- Dallas Innovates: OSPRI Merger Launch
- Wikipedia: Polymerase Chain Reaction
- Dallas News: New McKinney Biotech Firm
- Google Search: PCR Testing
- Dallas Innovates: Calloway’s Nursery Bioluminescent Flower
- Google Scholar: Biotechnology
- Dallas Innovates: New Tarleton State Biotech Institute
- Encyclopedia Britannica: Biotechnology
- Dallas Innovates: Biolabs Coworking Lab Opens
- Google News: Biotech Startups
Author: STAFF HERE DALLAS WRITER
DALLAS STAFF WRITER The DALLAS STAFF WRITER represents the experienced team at HEREDallas.com, your go-to source for actionable local news and information in Dallas, Dallas County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the State Fair of Texas, Deep Ellum Arts Festival, and Dallas International Film Festival. Our coverage extends to key organizations like the Dallas Regional Chamber and United Way of Metropolitan Dallas, plus leading businesses in telecommunications, aviation, and semiconductors that power the local economy such as AT&T, Southwest Airlines, and Texas Instruments. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREHouston.com, and HERESanAntonio.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
